

DAFTAR PUSTAKA

- Abdel-Qadir, H., Yan, A.T., Tan, M., Borgia, F., Piscione, F., Di Mario, C., Halvorsen, S., Cantor, W.J., Westerhout, C.M., Scheller, B., Le, M.R., Fernandez-Aviles, F., Sánchez, P.L. and Lee, D.S. (2015). Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. *Heart*, 101(19), pp.1554–1561. doi:<https://doi.org/10.1136/heartjnl-2015-307815>.
- Adam, A.A., Tiluata, L.J., Yunita, L., Putra, M.P., Wilujeng, N., Homalessy, L.V. and Hutabarat, D.C.F. (2021). A Clinical Profile of Acute Coronary Syndrome Patients in Kupang. *Indonesian Journal of Cardiology*, 42(4), pp.109–118. doi:<https://doi.org/10.30701/ijc.1194>.
- Alkhalil, M. and Choudhury, R.P. (2018). Reperfusion Treatment in Late Presentation Acute Myocardial Infarction. *Circulation: Cardiovascular Interventions*, 11(9). doi:<https://doi.org/10.1161/circinterventions.118.007287>.
- Anderson, J.A.M., Hirsh, J., Yusuf, S., Johnston, M., Afzal, R., Mehta, S.R., Fox, K.A.A., Budaj, A. and Eikelboom, J.W. (2010). Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial. *Journal of Thrombosis and Haemostasis*, 8(2), pp.243–249. doi:<https://doi.org/10.1111/j.1538-7836.2009.03705.x>.
- Armstrong, P.W., Gershlick, A.H., Goldstein, P., Wilcox, R., Danays, T., Lambert, Y., Sulimov, V., Rosell Ortiz, F., Ostojic, M., Welsh, R.C., Carvalho, A.C., Nanas, J., Arntz, H.-R., Halvorsen, S., Huber, K., Grajek, S., Fresco, C., Bluhmki, E., Regelin, A. and Vandenberghe, K. (2013). Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. *New England Journal of Medicine*, 368(15), pp.1379–1387. doi:<https://doi.org/10.1056/nejmoa1301092>.
- Bendary, A., Tawfik, W., Mahrous, M. and Salem, M. (2017). Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen. *Journal of Cardiovascular and Thoracic Research*, 9(4), pp.209–214. doi:<https://doi.org/10.15171/jcvtr.2017.36>.
- Biasin, M., Cordioli, N., Armani, I., Guerrieri, L., Parmegian, G., Sarai, A., Bonadiman, L., Lomi, S., Gambaro, A. and Ribichini, F.L. (2025). Lipid profiles in ST-elevation myocardial infarction with and without diabetes: the gap between prescription and targets. *International Journal of Cardiology*, 437, p.133474. doi:<https://doi.org/10.1016/j.ijcard.2025.133474>.
- Boulos, M., Sharif, Y., Assy, N. and Sharif, D. (2024). Significance of Smoking in Patients with Acute ST Elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: Evaluation of Coronary Flow, Microcirculation and Left Ventricular Systolic Function. *Hearts*, 5(1), pp.182–195. doi:<https://doi.org/10.3390/hearts5010012>.
- Budihardjo, R.S., Subagjo, A. and Prajitno, S. (2021). Reperfusion Therapy for ST-Elevation Myocardial Infarction at Dr. Soetomo General Academic Hospital Surabaya. *Cardiovascular and Cardiometabolic Journal (CCJ)*, 2(1), p.1. doi:<https://doi.org/10.20473/ccj.v2i1.2021.1-9>.
- Caldeira, D. and Pereira, H. (2019). Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review. *Revista Portuguesa de Cardiologia (English Edition)*, 38(4), pp.289–297. doi:<https://doi.org/10.1016/j.repce.2019.05.020>.
- Chandrashekhar, Y., Alexander, T., Mullasari, A., Kumbhani, D.J., Alam, S., Alexanderson, E., Bachani, D., Wilhelmus Badenhorst, J.C., Baliga, R., Bax, J.J., Bhatt, D.L., Bossone, E., Botelho, R., Chakraborty, R.N., Chazal, R.A., Dhaliwal, R.S., Gamra, H., Harikrishnan, S.P., Jeilan, M. and Kettles, D.I. (2020). Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income

- Countries. *Circulation*, 141(24), pp.2004–2025. doi:<https://doi.org/10.1161/circulationaha.119.041297>.
- Dangas, G., Mehran, R., Guagliumi, G., Caixeta, A., Witzenbichler, B., Aoki, J., Peruga, J.Z., Brodie, B.R., Dudek, D., Kornowski, R., Rabbani, L.E., Parise, H. and Stone, G.W. (2009). Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. *Journal of the American College of Cardiology*, 54(15), pp.1438–1446. doi:<https://doi.org/10.1016/j.jacc.2009.06.021>.
- De Luca, L., Uguccioni, M., Natale, E., Pugliese, M., Terranova, A., Biffani, E., De Lio, L., Di Piazza, V., Putini, R.L. and Musumeci, F. (2021). Effectiveness of fondaparinux vs unfractionated heparin following percutaneous coronary intervention in survivors of out-of-hospital cardiac arrest due to acute myocardial infarction. *European Journal of Clinical Pharmacology*, 77(10), pp.1563–1567. doi:<https://doi.org/10.1007/s00228-021-03152-7>.
- Dudek, D., Dziewierz, A., Rakowski, T., El Masri, N., Sorysz, D., Zalewski, J., Legutko, J., Zmudka, K., Piwowarska, W. and Dubiel, J.S. (2005). Time-to-reperfusion therapy influences outcome of patients with myocardial infarction subjected to facilitated PCI. *EuroIntervention*, 1, pp.309–314.
- Emilsson, O.E., Bergman, S., Mohammad, M.M., Olivecrona, G.O., Göteborg, M., Erlinge, D. and Koul, S. (2022). Pretreatment with heparin in patients with ST-segment elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). *EuroIntervention*, 18(9), pp.709–718. doi:<https://doi.org/10.4244/eij-d-22-00432>.
- Emilsson, O.E., Bergman, S., Mohammad, M.M., Olivecrona, G.O., Göteborg, M., Erlinge, D. and Koul, S. (2022). Pretreatment with heparin in patients with ST-segment elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). *EuroIntervention*, 18(9), pp.709–718. doi:<https://doi.org/10.4244/eij-d-22-00432>.
- Engel Gonzalez, P., Omar, W., Patel, K.V., de Lemos, J.A., Bavry, A.A., Koshy, T.P., Mullasari, A.S., Alexander, T., Banerjee, S. and Kumbhani, D.J. (2020). Fibrinolytic strategy for st-segment–elevation myocardial infarction. *Circulation: Cardiovascular Interventions*, [online] 13(9). doi:<https://doi.org/10.1161/circinterventions.120.009622>.
- Giralt, T., Carrillo, X., Rodriguez-Leor, O., Fernandez-Nofrerias, E., Rueda, F., Serra-Flores, J., Viguer, J.M., Mauri, J., Curos, A. and Bayes-Genis, A. (2015). Time-dependent effects of unfractionated heparin in patients with ST-elevation myocardial infarction transferred for primary angioplasty. *International Journal of Cardiology*, 198, pp.70–74. doi:<https://doi.org/10.1016/j.ijcard.2015.06.009>.
- Janjani, P., Motevaseli, S., Salimi, Y., Bavandpouri, S.M., Ziapour, A., Salehi, N. and Karami, S. (2023). Clinical and epidemiological profile of ST-segment elevation myocardial infarction patients in a megacity of west of Iran. *Health science reports*, [online] 6(5), p.e1187. doi:<https://doi.org/10.1002/hsr2.1187>.
- Kammler, J., Kypta, A., Hofmann, R., Kerschner, K., Grund, M., Sihorsch, K., Clemens Steinwender, Lambert, T., Wolfram Helml and Leisch, F. (2008). TIMI 3 flow after primary angioplasty is an important predictor for outcome in patients with acute myocardial infarction. *Clinical research in cardiology*, 98(3), pp.165–170. doi:<https://doi.org/10.1007/s00392-008-0735-9>.
- Karlsson, S., Andell, P., Mohammad, M.A., Koul, S., Olivecrona, G.K., James, S.K., Fröbert, O. and Erlinge, D. (2019). Editor's Choice- Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trial. *European Heart Journal: Acute Cardiovascular Care*, 8(1), pp.15–23. doi:<https://doi.org/10.1177/2048872617727723>.

- Lloyd, A., Steele, L., Fotheringham, J., Iqbal, J., Sultan, A., Teare, M.D. and Grech, E.D. (2016). Pronounced increase in risk of acute ST-segment elevation myocardial infarction in younger smokers. *Heart*, 103(8), pp.586–591. doi:<https://doi.org/10.1136/heartjnl-2016-309595>.
- Mehta, S.R., Tanguay, J.-F., Eikelboom, J.W., Jolly, S.S., Joyner, C.D., Granger, C.B., Faxon, D.P., Rupprecht, H.-J., Budaj, A., Avezum, A., Widimsky, P., Steg, P.G., Bassand, J.-P., Montalescot, G., Macaya, C., Di Pasquale, G., Niemela, K., Ajani, A.E., White, H.D. and Chrolavicius, S. (2010). Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *The Lancet*, 376(9748), pp.1233–1243. doi:[https://doi.org/10.1016/s0140-6736\(10\)61088-4](https://doi.org/10.1016/s0140-6736(10)61088-4).
- Mehta, S.R., Yusuf, S., Peters, R.J., Bertrand, M.E., Lewis, B.S., Natarajan, M.K., Malmberg, K., Rupprecht, H., Zhao, F., Chrolavicius, S., Copland, I., Fox, K.A. and Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001). Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet (London, England)*, 358(9281), pp.527–33. doi:[https://doi.org/10.1016/s0140-6736\(01\)05701-4](https://doi.org/10.1016/s0140-6736(01)05701-4).
- Muneeb, M., Khan, A.H., Khan Niazi, A., Khan, M.U., Chatha, Z.J., Kazmi, T. and Shahid, N. (2022). Patterns of Dyslipidemia Among Acute Coronary Syndrome (ACS) Patients at a Tertiary Care Hospital in Lahore, Pakistan. *Cureus*, 14(12). doi:<https://doi.org/10.7759/cureus.32378>.
- Palmer, J., Lloyd, A., Steele, L., Fotheringham, J., Teare, D., Iqbal, J. and Grech, E.D. (2019). Differential Risk of ST-Segment Elevation Myocardial Infarction in Male and Female Smokers. *Journal of the American College of Cardiology*, [online] 73(25), pp.3259–3266. doi:<https://doi.org/10.1016/j.jacc.2019.03.525>.
- Patti, G., Bárczi, G., Orlic, D., Mangiacapra, F., Colonna, G., Pasceri, V., Barbato, E., Merkely, B., Edes, I., Ostojic, M., Wijns, W. and Di Sciascio, G. (2011). Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. *Journal of the American College of Cardiology*, [online] 58(15), pp.1592–1599. doi:<https://doi.org/10.1016/j.jacc.2011.06.044>.
- Pinto, D.S., Frederick, P.D., Chakrabarti, A.K., Kirtane, A.J., Ullman, E., Dejam, A., Miller, D.P., Henry, T.D. and Gibson, C.M. (2011). Benefit of Transferring ST-Segment–Elevation Myocardial Infarction Patients for Percutaneous Coronary Intervention Compared With Administration of Onsite Fibrinolytic Declines as Delays Increase. *Circulation*, 124(23), pp.2512–2521. doi:<https://doi.org/10.1161/circulationaha.111.018549>.
- Qamar, A., Bhatia, K., Arora, S., Hendrickson, M., Gupta, P., Fatima, A., MP, G., Bansal, A., Batra, V., Ricciardi, M.J., Grines, C.L., Yusuf, J., Mukhopadhyay, S., Smith, S.C., Tyagi, S., Bhatt, D.L., Gulati, M. and Gupta, M.D. (2023). Clinical Profiles, Outcomes, and Sex Differences of Patients With STEMI. *JACC: Asia*, [online] 3(3), pp.431–442. doi:<https://doi.org/10.1016/j.jacasi.2022.12.011>.
- Reindl, M., Reinstadler, S.J., Feistritz, H., Theurl, M., Basic, D., Eigler, C., Holzknecht, M., Mair, J., Mayr, A., Klug, G. and Metzler, B. (2017). Relation of Low-Density Lipoprotein Cholesterol With Microvascular Injury and Clinical Outcome in Revascularized ST-Elevation Myocardial Infarction. *Journal of the American Heart Association*, 6(10). doi:<https://doi.org/10.1161/jaha.117.006957>.
- Sabatine, M.S., Cannon, C.P., Gibson, C.M., López-Sendón, J.L., Montalescot, G.,

- Theroux, P., Lewis, B.S., Murphy, S.A., McCabe, C.H., Braunwald, E. and Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators (2005). Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. *JAMA*, [online] 294(10), pp.1224–1232. doi:<https://doi.org/10.1001/jama.294.10.1224>.
- Sheikh-Taha, M. and Hijazi, Z. (2014). Evaluation of proper prescribing of cardiac medications at hospital discharge for patients with acute coronary syndromes (ACS) in two Lebanese hospitals. *SpringerPlus*, 3(1), p.159. doi:<https://doi.org/10.1186/2193-1801-3-159>.
- Sia, C.-H., Zheng, H., Ho, A.F.-W., Bulluck, H., Chong, J., Foo, D., Foo, L.-L., Lim, P.Z.Y., Liew, B.W., Tan, H.-C., Yeo, T.-C., Chua, T.S.J., Chan, M.Y.-Y. and Hausenloy, D.J. (2020). The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry. *Scientific Reports*, [online] 10, p.6799. doi:<https://doi.org/10.1038/s41598-020-63825-8>.
- Steele, L., Lloyd, A., Fotheringham, J., Sultan, A., Iqbal, J. and Grech, E.D. (2015). A retrospective cross-sectional study on the association between tobacco smoking and incidence of ST-segment elevation myocardial infarction and cardiovascular risk factors. *Postgraduate Medical Journal*, 91(1079), pp.492–496. doi:<https://doi.org/10.1136/postgradmedj-2015-133269>.
- Szumner, K., Oldgren, J., Lindhagen, L., Carrero, J.J., Evans, M., Spaak, J., Edfors, R., Jacobson, S.H., Andell, P., Wallentin, L. and Jernberg, T. (2015). Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Non-ST-Segment Elevation Myocardial Infarction. *JAMA*, 313(7), p.707. doi:<https://doi.org/10.1001/jama.2015.517>.
- Toluey, M., Ghaffari, S., Tajlil, A., Nasiri, B. and Rostami, A. (2019). The impact of cigarette smoking on infarct location and in-hospital outcome following acute ST-elevation myocardial infarction. *Journal of Cardiovascular and Thoracic Research*, [online] 11(3), pp.209–215. doi:<https://doi.org/10.15171/jcvtr.2019.35>.
- von Beckerath, N., Taubert, D., Pogatsa-Murray, G., SchömigE., Kastrati, A. and SchömigA. (2005). Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel. *Circulation*, 112(19), pp.2946–2950. doi:<https://doi.org/10.1161/circulationaha.105.559088>.
- Xie, F., Li, X., Xu, Y., Cheng, D., Xia, X., Lv, X., Yuan, G. and Peng, C. (2022). Estrogen Mediates an Atherosclerotic-Protective Action via Estrogen Receptor Alpha/SREBP-1 Signaling. *Frontiers in Cardiovascular Medicine*, 9. doi:<https://doi.org/10.3389/fcvm.2022.895916>.
- Zhang, R., Fan, Y., Xue, Y., Feng, Y., Dong, C., Wang, Y., Kou, P., Li, G., Ma, A. and Wang, T. (2022a). The LDL/HDL ratio predicts long-term risk of coronary revascularization in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: a cohort study. *Brazilian Journal of Medical and Biological Research*, 55. doi:<https://doi.org/10.1590/1414-431x2021e11850>.
- Zhang, S., Lin, Z., Yu, B., Liu, J., Jin, J., Li, G. and Dong, H. (2024). Smoking paradox in coronary function and structure of acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. *BMC Cardiovascular Disorders*, 24(1). doi:<https://doi.org/10.1186/s12872-024-04093-6>.
- Zhang, Z., Wu, H., Wang, T., Liu, Y. and Meng, C. (2022b). Mechanisms of Myocardial Damage Due to Hyperlipidemia: A Review of Recent Studies. *Medical Science Monitor*, 28, pp.e937051-1e937051-9. doi:<https://doi.org/10.12659/msm.937051>.

